A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria
Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This pilot and dose-ranging study will evaluate the efficacy, safety, and pharmacokinetics of
MTPS9579A compared with placebo in participants with chronic spontaneous urticaria (CSU)
refractory to antihistamines. This study comprises two parts. In Part 1, participants will be
randomized to receive MTPS9579A or placebo. On the basis of positive results from Part 1, a
dose-ranging Part 2 may be opened, where participants will be randomized to receive one of
four MTPS9579A doses or placebo.